Trabedersen is an antisense oligonucleotide therapeutic agent designed to inhibit the expression of Transforming Growth Factor-beta 2, a protein often associated with tumor progression and immune suppression… Read more
Trabedersen is an antisense oligonucleotide therapeutic agent designed to inhibit the expression of Transforming Growth Factor-beta 2, a protein often associated with tumor progression and immune suppression in malignant tumors. As a targeted gene silencing therapy, it has been investigated for its potential to reduce tumor growth and modulate the immune response. Analytical laboratories require high-quality reference standards, synthetic impurities, metabolites, and stable isotope-labelled compounds of this molecule to support rigorous scientific research. These materials are essential for accurate impurity profiling, method validation, and ongoing quality control during the development and testing of oligonucleotide-based therapeutics. By providing a comprehensive range of these related compounds, analytical workflows can reliably assess the purity, stability, and characterization of this complex biological drug throughout preclinical and clinical studies.